I-A2 Biotherapeutics, Inc., inkampani ye-biotechnology egxile ekwelapheni izimila eziqinile, imemezele namuhla ukuthi idatha ebalulekile ye-preclinical ehlobene neplathifomu yayo yokwelapha yeseli ye-Tmod™ ishicilelwe ku-Science Translational Medicine kanye ne-Journal for ImmunoTherapy of Cancer. Ukwelashwa kwe-Tmod™ kuklanyelwe iziguli ezinomdlavuza izimila zazo ezisusa ufuzo oluthile, futhi ukuhlolwa kofuzo kuvumela ukuhlonzwa kusenesikhathi kweziguli ezingase zizuze kulokho kwelashwa. I-Tmod™ therapy isebenzisa ukususwa okunjalo ukuze kucekelwe phansi izimila kuyilapho konga amaseli avamile, okungase kunikeze indlela entsha eqinile yokwelapha umdlavuza oqinile wesimila.
"Lawa maphepha amabili aveza inqwaba yobufakazi be-preclinical in vitro kanye ne-vivo obusekela ukusebenza okuqinile, okukhetha kakhulu kohlelo lwe-Tmod™, indlela entsha yokwelapha umdlavuza ebhekana ngqo nenkinga eyinhloko ye-oncology - ikhono imithi yomdlavuza yokuhlukanisa phakathi kwesimila namaseli avamile,” kusho uDkt. Alexander Kamb, oyiChief Scientific Officer kwa-A2 Bio.
Iphepha elanyatheliswa ngoMashi 2, 2022 ku-Science Translational Medicine (Sandberg et al., "Ukwelashwa kweseli okuklanyelwe ukukhomba i-antigen ye-CEA ngokuphepha ezigulini ezikhethiwe ezinamathumba aqinile") kuchaza ikhandidethi lasemtholampilo eliqondiswe kumathumba aqinile ekholoni kanye nokunye. izitho ezithuthukela esigabeni soku-1. UDkt. Han Xu, iPhini Likamongameli weTherapeutic Technology kwa-A2 Bio kanye nombhali ophezulu ephepheni, uthe: “Imininingwane yethu yangaphambi komtholampilo iphakamisa ukuthi lo muthi osuselwa kumaseli uzoba namandla omtholampilo. Ibhentshimakhi yokwelapha eqondiswe ku-CEA esebenzayo, kodwa ngaphandle kobuthi.
Iphepha elishicilelwe ngoJanuwari 28, 2022 kuJournal for ImmunoTherapy of Cancer (Tokatlian et al., "Ukwelashwa kweseli ye-Mesothelin ethize ye-CAR-T ehlanganisa indlela yokuphepha ye-HLA-gated ibulala amaseli wesimila ngokukhetha") ikhombisa ukusetshenziswa okungenzeka kwe-Tmod ™ T amaseli kumdlavuza wamaphaphu nezinye izimila eziqinile. UDkt. Agi Hamburger, iPhini Likamongameli we-Drug Discovery kanye nombhali ophezulu, waphawula: “Incwadi yethu ayichazi kuphela izici zethemba elisha elijabulisayo ezigulini ezinomdlavuza wamaphaphu kodwa futhi igqamisa ukuguquguquka okumangalisayo kwenkundla yethu ye-Tmod™, inkundla thina ithemba linganwetshwa ukuze kudaleke izindlela zokwelapha ezinye iziguli ezinomdlavuza esikhathini esizayo.”
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- “These two papers present a large body of preclinical in vitro and in vivo evidence that supports the robust, highly selective function of the Tmod™ system, a new approach to cancer therapy that addresses head-on the central problem of oncology –.
- “Our publication not only describes the properties of an exciting new prospect for lung cancer patients but also highlights the impressive modularity of our Tmod™ platform, a platform that we hope can be extended to create therapies for many other cancer patients in the future.
- , “A cell therapy designed to target the CEA antigen safely in selected patients with solid tumors”) describes a clinical candidate directed at solid tumors of the colon and other organs which is currently advancing toward Phase 1.
